PRESTO
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
- NCT04115007 ↗
- Active, not recruiting
- UNICANCER
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on PRESTO (oligometastatic hormone-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Topics in the commentary so far
Topics in 40 sources so far: early toxicity with metastasis-directed therapy; early efficacy assessments with metastasis-directed therapy.
From 13 authors, 3 of them verified clinicians. Automated from the 40 newest of 160 indexed sources (Oct 2025 – Oct 2026). Each topic is raised in at least two. Not an Erudio report: no source links. Not medical advice.
Indexed commentary on PRESTO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 78 posts on X | |
| 42 YouTube videos | |
| 40 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 550 (estimated)
- Primary outcomes
- Castration-resistant prostate cancer free survival
- Sponsor
- UNICANCER
- Start
- Jun 23, 2020
- Primary completion
- Jun 23, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04115007 · updated Jun 26, 2025
Publications
linked from the registry- Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021. PubMed 35602670